Want to join the conversation?
In 2Q16, $GEVO's R&D expense was $1.5MM versus $1.8MM in 2Q15, hurt by a reduction in employee related expense. SG&A dipped to $2.1MM in the quarter, mainly due to decrease in litigation legal expenses. Non-cash stock-based compensation was about $0.2MM in 2Q16.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)